Abstinence and Reduced Frequency of Use Are Associated with Improvements in Quality of Life Among Treatment-seekers with Cannabis Use Disorder

Overview

Journal Am J Addict

Specialty Psychiatry

Date 2018 Feb 20

PMID 29457671

Citations 15

Authors

Christina A Brezing

C Jean Choi

Martina Pavlicova

Daniel Brooks

Amy L Mahony

John J Mariani

Frances R Levin

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Many patients with cannabis use disorder (CUD) do not achieve or do not have abstinence as a goal of treatment, rather they reduce their use. Assessing outcome measures as they relate to functioning and reductions in cannabis use is an important area of study. Quality of life (QoL) shows promise as one such measure. Past studies have demonstrated gender differences in QoL and CUD. We aim to assess (1) the relationship between cannabis use and QoL and (2) gender effects in an outpatient medication treatment study for CUD.

Methods: Data from an 11-weeks, double-blind, placebo-controlled trial of lofexidine and dronabinol for CUD (n = 62) was analyzed. Pearson's correlations between baseline QoL as measured with the Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form (QLES-Q-SF) and cannabis use assessed with modified timeline follow-back (TLFB) were examined. Multiple linear regression models of cannabis use on end of study QLES-Q-SF were analyzed, while adjusting for baseline QLES-Q-SF, study arm, and gender. Moderation effects with gender were also tested.

Results: No significant association between baseline cannabis use and QoL was found. End of study abstinence (F 8.34, p = .006) and reduced proportion of using days (F = 9.48, p = .004) were each significantly associated with end of study QoL. Reduction in grams (F = 0.25, p = .62) was not associated with QoL at end of study. Gender was not a significant moderator.

Discussion And Conclusions: Abstinence and lower frequency of use are associated with higher QoL, regardless of gender.

Scientific Significance: This is the first time QoL has been demonstrated to change over the course of CUD medication treatment. QoL is an important outcome in CUD treatment.

Trial Registration: NCT01020019. (Am J Addict 2018;27:101-107).

Citing Articles

ADHD and Alcohol Use Disorder: Optimizing Screening and Treatment in Co-occurring Conditions.

Hernandez M, Levin F, Campbell A CNS Drugs. 2025; .

PMID: 39979544 DOI: 10.1007/s40263-025-01168-6.

Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de....

Bond B, Duric B, Spinazzola E, Trotta G, Chesney E, Li Z Can J Psychiatry. 2025; 70(3):182-193.

PMID: 39810593 PMC: 11733868. DOI: 10.1177/07067437241290187.

Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials.

Amin-Esmaeili M, Farokhnia M, Susukida R, Leggio L, Johnson R, Crum R Addiction. 2024; 119(5):833-843.

PMID: 38197836 PMC: 11009085. DOI: 10.1111/add.16409.

A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder.

Sahlem G, Kim B, Baker N, Wong B, Caruso M, Campbell L Drug Alcohol Depend. 2023; 254:111035.

PMID: 38043228 PMC: 10837319. DOI: 10.1016/j.drugalcdep.2023.111035.

Perceived Risks and Therapeutic Benefits of Cannabis Among College Students Amidst the COVID-19 Pandemic.

Espinoza S, Lagunas M, Claudia R, Lovell J Cannabis. 2023; 6(3):18-33.

PMID: 38035168 PMC: 10683751. DOI: 10.26828/cannabis/2023/000157.

References

Goldenberg M, IsHak W, Danovitch I . Quality of life and recreational cannabis use. Am J Addict. 2016; 26(1):8-25. DOI: 10.1111/ajad.12486. View

Petry N, Alessi S, Hanson T . Contingency management improves abstinence and quality of life in cocaine abusers. J Consult Clin Psychol. 2007; 75(2):307-15. DOI: 10.1037/0022-006X.75.2.307. View

IsHak W, Mirocha J, Christensen S, Wu F, Kwock R, Behjat J . Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial. Depress Anxiety. 2013; 31(8):707-16. PMC: 4777696. DOI: 10.1002/da.22152. View

Mariani J, Brooks D, Haney M, Levin F . Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug Alcohol Depend. 2010; 113(2-3):249-51. PMC: 3025094. DOI: 10.1016/j.drugalcdep.2010.08.008. View

Levin F, Mariani J, Pavlicova M, Brooks D, Glass A, Mahony A . Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015; 159:53-60. PMC: 4729291. DOI: 10.1016/j.drugalcdep.2015.11.025. View

Gates P, Sabioni P, Copeland J, Le Foll B, Gowing L . Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016; (5):CD005336. PMC: 4914383. DOI: 10.1002/14651858.CD005336.pub4. View

Sherman B, McRae-Clark A . Treatment of Cannabis Use Disorder: Current Science and Future Outlook. Pharmacotherapy. 2016; 36(5):511-35. PMC: 4880536. DOI: 10.1002/phar.1747. View

IsHak W, Greenberg J, Cohen R . Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord. 2013; 151(1):59-65. PMC: 4167729. DOI: 10.1016/j.jad.2013.05.048. View

Gonzalez-Saiz F, Lozano Rojas O, Iraurgi Castillo I . Measuring the impact of psychoactive substance on health-related quality of life: an update. Curr Drug Abuse Rev. 2009; 2(1):5-10. DOI: 10.2174/1874473710902010005. View

10.

Rubio J, Olfson M, Villegas L, Perez-Fuentes G, Wang S, Blanco C . Quality of life following remission of mental disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2013; 74(5):e445-50. DOI: 10.4088/JCP.12m08269. View

11.

Dey M, Gmel G, Mohler-Kuo M . Body mass index and health-related quality of life among young Swiss men. BMC Public Health. 2013; 13:1028. PMC: 3840558. DOI: 10.1186/1471-2458-13-1028. View

12.

Morgan M, Landron F, Lehert P . Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin Exp Res. 2004; 28(1):64-77. DOI: 10.1097/01.ALC.0000108652.73143.4B. View

13.

Schechter D, Endicott J, Nee J . Quality of life of 'normal' controls: association with lifetime history of mental illness. Psychiatry Res. 2007; 152(1):45-54. PMC: 2291021. DOI: 10.1016/j.psychres.2006.09.008. View

14.

Francois C, Rahhali N, Chalem Y, Sorensen P, Luquiens A, Aubin H . The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients. PLoS One. 2015; 10(6):e0129289. PMC: 4460126. DOI: 10.1371/journal.pone.0129289. View

15.

Gruber A, Pope H, Hudson J, Yurgelun-Todd D . Attributes of long-term heavy cannabis users: a case-control study. Psychol Med. 2003; 33(8):1415-22. DOI: 10.1017/s0033291703008560. View

16.

Hser Y, Mooney L, Huang D, Zhu Y, Tomko R, McClure E . Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017; 81:53-58. PMC: 5607644. DOI: 10.1016/j.jsat.2017.07.012. View

17.

Hays J, Croghan I, Baker C, Cappelleri J, Bushmakin A . Changes in health-related quality of life with smoking cessation treatment. Eur J Public Health. 2010; 22(2):224-9. DOI: 10.1093/eurpub/ckq137. View

18.

Mitchell S, Gryczynski J, Schwartz R, Myers C, OGrady K, Olsen Y . Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use. J Psychoactive Drugs. 2015; 47(2):149-57. PMC: 4425232. DOI: 10.1080/02791072.2015.1014948. View

19.

Cougle J, Hakes J, Macatee R, Chavarria J, Zvolensky M . Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiatr Res. 2015; 66-67:135-41. DOI: 10.1016/j.jpsychires.2015.05.004. View

20.

Tiffany S, Friedman L, Greenfield S, Hasin D, Jackson R . Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction. 2011; 107(4):709-18. PMC: 3257402. DOI: 10.1111/j.1360-0443.2011.03581.x. View